Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,093 | -1,902 | -16,540 | -15,122 | -14,137 |
| Depreciation Amortization | 540 | 269 | 1,055 | 791 | 512 |
| Accounts receivable | 1,584 | -1,084 | -3,319 | 454 | 976 |
| Accounts payable and accrued liabilities | 352 | -728 | -744 | -1,304 | -226 |
| Other Working Capital | 5,896 | 2,644 | -6,318 | -5,579 | -1,118 |
| Other Operating Activity | 1,793 | 3,593 | 10,768 | 5,990 | 2,963 |
| Operating Cash Flow | $6,072 | $2,792 | $-15,098 | $-14,770 | $-11,030 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -96 | -91 | -334 | -162 | -110 |
| Investing Cash Flow | $-96 | $-91 | $-334 | $-162 | $-110 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 7,747 | N/A | N/A |
| Other Financing Activity | -11 | -1 | -93 | -25 | -7 |
| Financing Cash Flow | $-11 | $-1 | $7,654 | $-25 | $-7 |
| Beginning Cash Position | 20,441 | 20,441 | 28,219 | 28,219 | 28,219 |
| End Cash Position | 26,406 | 23,141 | 20,441 | 13,262 | 17,072 |
| Net Cash Flow | $5,965 | $2,700 | $-7,778 | $-14,957 | $-11,147 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,072 | 2,792 | -15,098 | -14,770 | -11,030 |
| Capital Expenditure | -101 | -91 | -334 | -162 | -110 |
| Free Cash Flow | 5,971 | 2,701 | -15,432 | -14,932 | -11,140 |